Development and implementation of the quality control panel of RT-PCR and real-time RT-PCR for avian influenza A (H5N1) surveillance network in mainland China by Gao, Rongbao et al.
RESEARCH ARTICLE Open Access
Development and implementation of the quality
control panel of RT-PCR and real-time RT-PCR for
avian influenza A (H5N1) surveillance network in
mainland China
Rongbao Gao
1, Yan Gao
1, Leying Wen
1, Ming Shao
2, Shumei Zou
1, Changgui Li
2, Lei Yang
1, Xiyan Li
1, Wei Wang
1,
Yuelong Shu
1*
Abstract
Background: Reverse transcription PCR (RT-PCR) and real time RT-PCR (rRT-PCR) have been indispensable methods
for influenza surveillance, especially for determination of avian influenza. The movement of testing beyond
reference lab introduced the need of quality control, including the implementation of an evaluation system for
validating personal training and sample proficiency testing.
Methods: We developed a panel with lysates of seasonal influenza virus (H1N1, H3N2 and B), serials of diluted
H5N1 virus lysates, and in-vitro transcribed H5 hemaglutinin (HA) and an artificial gene RNAs for RT-PCR and rRT-
PCR quality control assessment. The validations of stability and reproducibility were performed on the panel.
Additionally, the panel was implemented to assess the detection capability of Chinese human avian influenza
networks.
Results: The panel has relatively high stability and good reproducibility demonstrated by kappa’s tests. In the
implementation of panel on Chinese human avian influenza networks, the results suggested that there were a
relatively low number of discrepancies for both concise and reproducibility in Chinese avian influenza virus net
works.
Conclusions: A quality control panel of RT-PCR and real-time RT-PCR for avian influenza A (H5N1) surveillance
network was developed. An availably statistical data, which are used to assess the detection capability of networks
on avian influenza virus (H5N1), can be obtained relatively easily through implementation of the panel on
networks.
Background
National and international efforts to enhance early disease
detection and to increase diagnostic capacity have stimu-
lated the formation of laboratory networks within and
between public, animal, and even plant health areas. The
success of these laboratory networks can be attributed to
the implementation of standardized procedures and assays,
specific training programs as well as a demonstrated
proficiency samples. So far, avian influenza surveillance
networks have formed for performance in many countries
[1,2]. Highly pathogenic avian influenza virus (HPAIV)
H5N1 continues to pose a significant threat to human
health [3,4], although it remains a zoonotic infection [5,6].
A surveillance network with strong detection capability is
required to detect any evidence that the virus has acquired
the ability to transmit between humans or to emerge as
the next pandemic strain.
The Chinese influenza surveillance scheme aims to
reduce the burden of disease associated with influenza in
China by collecting and exchanging timely information
on influenza activity. It provides relevant information
* Correspondence: yshu@vip.sina.com
1Dept. of Influenza, Chinese National Influenza Center, State Key Laboratory
for Molecular Virology and Genetic Engineering, National Institute for Viral
Disease Control and Prevention, Chinese center for disease control and
prevention (China CDC), Beijing 100052, PR China
Full list of author information is available at the end of the article
Gao et al. BMC Infectious Diseases 2011, 11:67
http://www.biomedcentral.com/1471-2334/11/67
© 2011 Gao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.about influenza to health professionals and the general
public, and contributes to the annual determination of
the influenza vaccine content and to Chinese influenza
pandemic preparedness activities. Compared with seaso-
nal influenza surveillance in China, Chinese avian influ-
enza surveillance networks have an independent
infrastructure and information flow (Figure 1). Chinese
national influenza centre (CNIC), that was established in
1957 and was designed as the 5
th WHO collaborating
centre (WHO-CC) for reference and research of influ-
enza in 2009 [7], would perform final confirmation for
each suspected case in mainland China. The local labora-
tories of Chinese avian influenza surveillance networks
could need more experiences in laboratory activities in
addition to following reasons: So far, avian influenza
H5N1 viruses isolated from human still are highly patho-
genic [8,9]; Documented studies suggested that the virus
has potent ability of human-to-human transmission [10],
and the pandemic threat from highly pathogenic avian
influenza viruses (HPAIV) H5N1 has not been dimin-
ished [11,12].
It is common knowledge that reliable detection
techniques are necessary for influenza surveillance.
Conventional methods for the detection of influenza
viruses are virus isolation through inoculating samples
into embryonated hen egg or by cell culture, and follow-
ing to do HA and/or NA subtyping by serological meth-
ods (e.g., hemagglutinin inhibition (HI) assay). However,
it should be a big limitation to emergency cases hap-
pened since an incubation period up to 1-2 weeks is
often needed to achieve the subtype information later
[13], and not all network laboratories meet the certifi-
cated requirements for HPAIV isolation. Molecular
methods, specifically nucleic acid assay methods such as
RT-PCR and rRT-PCR with high sensitivity and specifi-
city have had indispensable effect on laboratory rapid
diagnosis of HPAIV. So far, almost all influenza net-
works in China have developed and applied PCR detec-
tion system. However, PCR as a diagnostic tool requires
a high degree of technological expertise including opera-
tion skill and procedure, environment support in addi-
tion to primers/probes and reagents. Therefore, quality
control assessment (QCA) will be required to assess net-
work performance. In this study, we developed a quality
control panel for avian influenza A (H5N1) RT-PCR
and rRT-PCR, and used the panel to implement
Figure 1 Infrastructure and information flow of Chinese avian surveillance scheme. Vir, virological specimens; CNIC, Chinese National
influenza centre; Local CDC, local centre for disease control and prevention from China’s Provinces, municipalities & Autonomous Regions; WHO,
world health organization; WHO CC, WHO collaborating centre for reference and research of influenza.
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from China’s Provinces, Autonomous Regions &
Municipalities.
Methods
Viruses
The viral strains used in this study include endemic sea-
sonal influenza viruses (H1N1, H3N2, B) of China and
avian influenza virus H5N1 (A/Guangdong/1/2005). The
viruses were propagated in embryonated eggs. Virus
titers were tested using hemagglutinin assay with turkey
red blood cells.
In-vitro transcribed RNA synthesis
In vitro transcribed hemaglutinin (HA) gene RNA of A/
Anhui/1/2005 (H5N1) was used to determine the detec-
t i o nl i m i to ft h ea s s a y .T h ee n t i r eg e n eH Aw a ss y n t h e -
sized and cloned into vector pSC-B (Stratagene, USA)
according to the manufacturer’s instructions. Gene
sequence was confirmed by ABI Prism 3730 sequencer
(Applied Biosystems, USA). The plasmid with T7 pro-
moter was linearized by restriction enzyme Sac-I and
then purified using DNA clean-up kit. DNA concentra-
tion was measured as OD units at 260 nm. One μgo f
linearized plasmid DNA was transcribed using Ribop-
robe in vitro transcription system kit (Promega, USA)
from the T7 promoter according to the manufacturer’s
instructions. The transcribed RNA was purified using
phenyl/chloroform solution and was quantified by spec-
trophotometer. RNA copy number was then determined
following the method of Fronhoffs [14].
Preparation of internal positive control (IPC) RNA
To control the possible cross-contamination in the pro-
gress of RT-PCR, an artificial gene with modified H5
HA segment which can be amplified by RT-PCR pri-
mers H5 (Table 1) was involved into the panel. The arti-
ficial gene is synthesized by inserting a 138 bp outlying
g e n ei n t ot h em i d d l eo fa nH 5H Ag e n es e g m e n t ,a n d
can be easily identified if RT-PCR amplification is per-
formed on both segments using the same primer set as
mentioned below. Therefore, the gene can be as IPC.
The IPC gene segment was inserted into pGEM-T easy
vector (Promega, USA) to make in vitro transcribed IPC
RNA.
RT-PCR and rRT-PCR
The primers/probes of RT-PCR and rRT-PCR followed
WHO released primer/probe sets for lab diagnosis on of
HPAI H5N1 [15]. RT-PCR using QIAGEN OneStep RT-
PCR kit (QIAGEN, Germany) was performed to amplify
Matrix (M), Hemagglutinin (HA) and neuraminidase
(NA) gene of avian influenza virus H5N1, respectively.
The reaction is completed in total volume of 25 μlw i t h
10 pM primer. The reaction mixture was incubated with
5 μl RNA at following temperature cycles. Firstly, the
reverse transcription reaction was finished by 1 cycle at
60°C for 1 min, 42°C for 10 min, and 50°C for 30 min.
Gene targets was then amplified by 1 cycle at 94°C for
15 min and 35 cycles at 94°C for 30 s, 52°C for 30 s and
72°C for 1 min each, and 1 cycle at 72°C for 5 min
respectively. The amplification products were arrayed on
1.5% electrophoresis agarose gel. The sizes of target
genes are 210 bp, 219 bp and 615 bp corresponding M,
HA and NA gene, respectively. rRT-PCR for identifica-
tion of all influenza A (FluA) and H5 influenza subtyp-
ing (H5) was performed using a fluorescently labeled
TaqMan probe to enable continuous monitoring of
amplicon formation. Primer and probe concentrations
were 40 pM and 10 pM, respectively. The reaction is
completed in total volume of 25 μl performed by Quanti-
Tect Probe PCR Kit (QIAGEN, Germany). The reaction
mixture was incubated with 5 μl RNA at following tem-
perature cycles. Firstly, the reverse transcription reaction
was finished by 1 cycle at 50°C for 30 min. Gene targets
were then amplified by 1 cycle at 94°C for 15 min and 45
cycles at 94°C for 15 s, 55°C for 30 s and 72°C for 30 s
each.
Combination of the panel
The panel was designed to include two groups: virus
lysates and in vitro transcribed RNA. The viruses
were lysised in biosafety level-2 (for seasonal influenza
viruses) or -3 (for avian influenza virus H5N1) con-
tainment laboratory using lysis buffer RLT (QIAGEN,
Germany) as described in the manufacturer’si n s t r u c -
tions. The virus lysate group was comprised of one
viral each of seasonal influenza viruses (H1N1, H3N2
and type B) and six vials of 10-fold diluted H5N1
virus (including four vials of detectable samples and
two vials of undetectable samples according the pret-
ests). The in vitro transcribed RNA group included
six vials of 10-fold diluted H5 HA and one vial of
IPC. Both groups used one viral sample of water as a
blank control. Each viral covered enough sample for
twice tests with all primers/probes as mentioned
above. To ensure the consistency of the samples, 150
aliquots for each sample were prepared. Unique ID
numbers were assigned to each sample to allow for
single blinded detection.
Table 1 Strength of agreement responded to value of 
Value of  Strength of agreement
<0.20 Poor
0.21-0.40 Fair
0.41-0.60 Moderate
0.61-0.80 Good
0.81-1.00 Very good
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As the flow of evaluation and implementation shown in
Figure 2, serial detection was performed to evaluate the
panel’s reproducibility. The panel was subjected to four
different temperature conditions: normal storage at
-80°C, 4 days in an ice box, 4 days in an ice box fol-
lowed by 3 days at -80°C, and 2 weeks at 4°C. The
panels with different treatments were then detected by
independent technicians from two Chinese national
reference laboratories (CNIC and the Chinese national
reference laboratory for PCR diagnostic reagent) using
the RT-PCR and rRT-PCR methods previously outlined.
All detections were completed under the single blinded
method. To validate the Chinese Local CDC’s capability
of identifying human avian influenza virus infection by
RT-PCR or rRT-PCR, the aforementioned panel was
implemented in 30 Local CDC laboratories (LL1~30)
from China’s Provinces, Municipalities & Autonomous
Regions. These labs that are members of the Chinese
influenza surveillance network utilized the same
reagents and protocols as the Chinese National Refer-
ence Laboratories. The panel and reagents were trans-
ported to the labs by FedEx. A request was made to
have all data submitted to the Chinese national influ-
enza center before the proposed deadline date. The
detections were required finished under single blinded
method with a designated protocol.
Statistical method
Kappa’s tests were performed to determine the inter-rater
agreement between variable technicians, PCR machines
and laboratories, and between CNIC and local labs as
well using SPSS statistics 17.0 software. The kappa coeffi-
cient was introduced by Cohen [16] as a chance-
corrected index of agreement (CCIA) between categorical
variables. The K value can be interpreted as Table 1 [17].
Results
Description of the panel as RNA reference
The panel is designed to validate and enhance Chinese
local lab of avian influenza network’s ability in determi-
nation of the HPAI H5N1 virus since nucleic acid detec-
tion is the only available method for the determination
of suspected H5N1 case in present local CDC of China.
To validate the extraction and/or PCR procedure in the
progress of detection, virus lysate and in vitro tran-
scribed RNA were introduce into the panel. Addition-
ally, an artificially modified HA gene segment, which
can be amplified into bigger segments than viral gene in
RT-PCR (Figure 3A), was integrated into the in vitro
Figure 2 Flow of validation and implementation for the RT-PCR and rRT-PCR panel.
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(IPC). This IPC allowed for validation of cross contami-
nation since it is common to present two bands in
gel product under cross-contamination happened
(Figure 3B). H2O was utilized as blank control for both
lysates and in vitro transcribed RNA samples. The sam-
ples for each panel were prepared in duplicate to assess
self-reproducibility. In total, 36 vials of uniquely coded
sample were included in every panel.
Validation of detectable samples in the panel
We performed detection on 8 panels selected at ran-
dom to validate the detectable samples in the panel.
As shown in Table 2, H5N1-1 and H5N1-2 lysates
were detectable in each assay by the both RT-PCR
and rRT-PCR. In vitro-transcribed RNA H5-1~H5-3
was detectable in each assay by H5 primer sets of
both RT-PCR and rRT-PCR. H5N1-3 and H5N1-4
lysates combined with in-vitro transcribed RNA H5-4
were detectable in part of assays, which can be called
“gray zone” samples (GZS). H3N2 and H1N1 lysates
were positive just by Flu A of rRT-PCR. IPC was posi-
tive by H5 of RT-PCR only. All remaining unmen-
tioned samples were undetectable by both RT-PCR
and rRT-PCR.
Validation of applicability for the panel
To validate the applicability of the panel, we performed
serials of parallel detections on the panel including
between different technicians, PCR machines, treatment
conditions, and between 2 national reference labora-
tories as well. Kappa’s tests were performed to analyze
the CCIA between the detection results with varying
factors. As shown in Table 3, CCIAs showed to be very
good between varying factors in both RT-PCR and rRT-
PCR (k>0.81) except a good rRT-PCR CCIA between
conditions C1 and C4 (k = 0.804). Additionally, all of
results showed completely matching (k = 1) between
general PCR machines (M1~3), treatments on panel
(C1~3) and laboratories (lab1~2).
Implementation of the panel in local lab of Chinese
influenza net work
All of the implementation data were obtained before
the proposed deadline date with the exception of RT-
PCR results of LL22 and rRT-PCR results of LL9. The
Figure 3 The results of the RT-PCR for H5N1 HA and artificially
modified HA gene. A-1/B-1: DL2000 molecular weight marker; A-2:
HA amplicon of H5N1 virus HA gene; A-3: Amplicon of IPC gene; B-
2: Typical IPC amplificons under cross contamination happened.
Table 2 the sensitivity validation of the quality control
system
Variation RT-PCR rRT-PCR
AM H5 N1 FluA H5
Virus lysate
H5N1-1 8/8
a 8/8 8/8 7/7 7/7
H5N1-2 8/8 8/8 8/8 7/7 7/7
H5N1-3 8/8 8/8 2/8 5/7 5/7
H5N1-4 3/8 1/8 1/8 1/7 2/7
H5N1-5 0/8 0/8 0/8 0/7 0/7
H5N1-6 0/8 0/8 0/8 0/7 0/7
H2O 0/8 0/8 0/8 0/7 0/7
H3N2 0/8 0/8 0/8 7/7 0/7
H1N1 0/8 0/8 0/8 7/7 0/7
FluB 0/8 0/8 0/8 0/7 0/7
In vitro transcribed RNA
H5-1 0/8 8/8 0/8 0/7 7/7
H5-2 0/8 8/8 0/8 0/7 7/7
H5-3 0/8 8/8 0/8 0/7 7/7
H5-4 0/8 7/8 0/8 0/7 3/7
H5-5 0/8 0/8 0/8 0/7 0/7
H5-6 0/8 0/8 0/8 0/7 0/7
IPC 0/8 8/8 0/8 0/7 0/7
H2O 0/8 0/8 0/8 0/7 0/7
aPositive tests/total tests.
Table 3 The comparison of reproducibility between
technicians, machines and conditions changes
Comparison RT-PCR rRT-PCR
n Kappa ± SE
a n Kappa ± SE
Technician
T1&T2 132 0.976 ± 0.022 129 0.908 ± 0.040
Machines
M1&M2 88 1.000 ± 0.000 / /
M1&M3 88 1.000 ± 0.000 / /
M4&M5 / / 72 0.870 ± 0.073
Conditions
C1&C2 64 1.000 ± 0.000 64 1.000 ± 0.000
C1&C3 64 1.000 ± 0.000 64 1.000 ± 0.000
C1&C4 64 0.925 ± 0.052 64 0.804 ± 0.083
Labs
Lab1 & Lab2 84 1.000 ± 0.000 72 1.000 ± 0.000
aSE is the abbreviation of Standard Error.
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tests without GSZ between CNIC and local labs, and
of local labs’ self-reproducibility in duplicates. The
results suggested that the CCIAs presented parabola-
like distribution not only between CNIC and local labs
but also in self-reproducibility (Figure 4), and RT-PCR
has better CCIA in both cross concordance and self-
reproducibility than rRT-PCR (Table 4). Most of
laboratories presented good or very good CCIA in
both RT-PCR and rRT-PCR. However, discrepancies in
concordance and reproducibility were still observed.
One lab each (3.45%) presented with fair and moderate
RT-PCR CCIA in the cross concordance. Additionally,
one lab each (3.45%) responded to poor and moderate
rRT-PCR CCIA, respectively. And one (3.45%), two
(6.9%) and two (6.9%) of 29 labs presented poor, fair
and moderate rRT-PCR CCIA in self-reproducibility,
respectively.
Discussion
QCA studies for laboratory diagnostics of avian influ-
enza virus help to monitor the quality of service of the
participating centers, to highlight problems in particular
tests or specific laboratories, and to give assurance to
those centers that perform well. The objective of the
QCA task group are: (i) to organize QCAs; (ii) to pre-
pare and distribute quality control panels; (iii) to analyze
and report the results; and (iv)to organize follow-up
help [18]. In this study, we developed a quality control
panel of RT-PCR and rRT-PCR for avian influenza A
(H5N1) surveillance networks in mainland China. The
panel with relatively high stability and good reproduci-
bility was used to implement assessment of avian influ-
enza virus detection in 30 local CDC’sl a bf r o mC h i n a ’s
Provinces, Autonomous Regions & Municipalities. The
results suggested that more than 90% Chinese local
influenza labs have good capability to perform detection
and identification of avian influenza virus H5N1 by RT-
PCR and/or rRT-PCR.
The developed quality control panel included the sam-
ples for assessment of the specificity, sensitivity and
reproducibility. RT-PCR or rRT-PCR have played very
important role and have been extensively used in infec-
tious diseases surveillance, especially in emergency dis-
eases because of their good specificity, high sensitivity
and quick results. However, it is not uncommon to pre-
senting false positive or false negative results if techno-
logical operation or lab environment is not qualified
[19-23]. In the present study, the developed quality con-
trol panel included samples for assessment of sensitivity,
Figure 4 The distribution of local labs’ CCIA. A and B diagrams present RT-PCR and rRT-PCR between local laboratories and CNIC without
GZS, respectively; C and D diagrams present the RT-PCR and rRT-PCR self-reproducibility Kappa coefficient of local laboratories, respectively.
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that included a series of diluted H5N1 virus lysates and
in vitro transcribed H5 HA RNA for sensitivity assess-
ment, and seasonal influenza (H1N1, H3N2 and FluB)
for cross-specific detection. Known negative samples
and an artificial gene RNA were also integrated into the
panel for assessment of cross contamination. Addition-
ally, the panel included duplicate samples for assessment
of self-reproducibility.
The panel is relatively stability with high reproducibil-
ity. Individual, full interpreted, concise and informative
reports should be the standard practice when QCA is
implemented in networks [24,25]. It is common that
RNA samples easily degenerate if involving undependable
processing. Therefore the stability and reproducibility of
the panel is very important in implementation of panel.
In present study, we performed 3 different treatments on
the panel. Firstly, to simulate keeping condition and the
amount of time needed in the transportation via FedEx,
the panel was placed in an ice box for four days. The sec-
ond treatment consisted of keeping the panel in an ice
box for four days then storing at -80°C for three days.
This condition was designed to evaluate the effects of
samples being delivered and stored over the weekend
when processing is unavailable. The final treatment was
keeping the panel at 4°C for two weeks to assess unpre-
dictable variation when the panel was implemented. In
comparison to the normal storage condition of -80°C, the
results suggested that no obvious affection happened on
the three treatments as shown by very good CCIA. Addi-
tionally, the panel presented very high reproducibility as
demonstrated by very good CCIA between different tech-
nicians, PCR machines and laboratories.
There were a relatively low number of discrepancies
for both concise and reproducibility in this QCA exer-
cise in Chinese avian influenza virus networks. In this
implement of QCA, 2/29 laboratories presented fair or
moderate rRT-PCR identification for the sample in the
developed quality control panel. And 5/29 laboratories
presented poor, fair or moderate reproducibility in
excise of quality control panel. However, quality assess-
ment is an educational exercise, not a punitive action;
its aim is to assist laboratories in their continuous effort
towards a higher quality services as we communicated
with local labs before the implementation of assessment.
Therefore, it was rather discouraging that those labora-
tories with inaccurate sizing results did not participate
the following years. To be opposite, in this quality con-
trol exercise, these laboratories participated a specific
training for the diagnosis of the avian influenza virus
H5N1 after the QCA. In addition, to our knowledge, it
is very difficult to develop a standard cut-off value on
rRT-PCR. Professional experience should play important
role on the dispose of results, especially, when the high
Ct value was present. Besides, rRT-PCR should be fluc-
tuated easier than RT-PCR as general knowledge men-
t i o n e d .T og e tt o g e t h e r ,i ts h o u l db eu s e dt oe x p l a i n
why the RT-PCR has better CCIA in both cross concor-
dance and self-reproducibility than rRT-PCR in the
implement of QCA.
We cannot know if the QCA results reflected the true
practices in diagnosis of avian influenza A (H5N1).
QCA is voluntary and might be biased towards better
performing laboratories as strongly recommended.
Besides, QCA samples are always treated by the same
way as routine referrals. However, many laboratories
have never attributed the large samples or enrolled in
the daily sample pool. Thus, the error rates found could
still be overestimated on true laboratory performance.
Conclusion
We developed a quality control panel of RT-PCR and
rRT-PCR for avian influenza virus H5N1 surveillance.
The panel showed relatively good stability and high
reproducibility which is possible for the implement of
the panel. An availably statistical data, which are used to
assess the detection capability of net works on avian
influenza virus (H5N1), can be obtained relatively easily
through implementation of the panel on networks.
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